Nonopioid motor effects of dynorphin A and related peptides: Structure dependence and role of the N-methyl-D-aspartate receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 2, 1997, Pages 604-610

  Shukla, Vijay K ^a   Prasad, Jyoti A ^a   Lemaire, Simon ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 PHOSPHONOMETHYL 3 HEPTENOIC ACID; DEXTRORPHAN; DIZOCILPINE; DYNORPHIN A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; INHIBITION KINETICS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION;

2-AMINO-5-PHOSPHONOVALERATE; AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; BRAIN; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYNORPHINS; MALE; MICE; MOLECULAR SEQUENCE DATA; MOTOR ACTIVITY; NARCOTICS; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030783867     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. CAUDLE, R. M. AND ISAAC, L.: Intrathecal dynorphinl (1-13) results in an irreversible loss of tail-flick reflex in rats. Brain Res. 435: 1-6, 1987.
2. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108, 1973.
3. COLLINGRIDGE, G. L. AND BLISS, T. V. P.: Memories and NMDA receptors and LTP. Trends Neurosci. 18: 54-56, 1995.
4. DUBNER, R. AND RUDA, M. A.: Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 15: 96-103, 1992.
5. 3H]dynorphin A-(1-13) binding sites in the rat heart. J. Mol. Cell. Cardiol. 25: 983-991, 1993.
6. 3H]noradrenaline uptake in rat heart. Reg. Peptides suppl. 1, S259-S260, 1994a.
7. 3H]CGP-39653 binding to rat brain membranes. Eur. J. Pharmacol. 271: 241-244, 1994b.
8. DUMONT, M. AND LEMAIRE, S.: Opioid and non-opioid cardiovascular effects of dynorphins. Adv. Pharmacol. 37: 1-33, 1997.
9. ELMER, E., KOKAIA, M., KOKAIA, Z., FERENCZ, I. AND LINDVAIX, O.: Delayed kindling development after rapidly recurring seizures: Relation to mossy fiber sprouting and neurotrophin, GAP-43 and dynorphin gene expression. Brain Res. 712: 19-34, 1996.
10. FADEN, A. I.: Dynorphin increases extracellular levels of excitatory amino acids in the brain through non-opioid mechanism. J. Neurosci. 12: 425-429, 1992.
11. GARZON, J. G., SANCHEZ-BLAZQUEZ, P., GERHART. J., LOH, H. H. AND LEE, N. M.: Dynorphin 1-13: Interaction with other opiate ligands bindings in vitro. Brain Res. 302: 392-396, 1984.
12. 2-dynorphin-(1-11) in rats. Life Sci. 27: 883-892, 1980.
13. 1]dynorphin A-(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay. J. Pharmacol. Exp. Ther. 273: 802-807, 1995.
14. HUNTER, J. C., PURBRICK, S., BODEN, P. R. AND WOODRUFF, G. N.: Dynorphin interaction with the NMDA receptor/channel complex: correlation with spinal cord injury. Reg. Peptides 1: suppl, S89-S90, 1994.
15. KOEK, W. AND COLPAERT, F. C.: Selective blockade of N-methyl-d-aspartate (NMDA)-induced convulsions by NMDA antagonists: Relationship with phencyclidine-like behavioral effects. J. Pharmacol. Exp. Ther. 252: 349-357, 1990.
16. LE, H.-T., MICHELOT, R., DUMONT, M., SHUKLA, V. K., MAYER, M., NGUYEN, K. P.-P., RUAN, H., AND LEMAIRE, S.: Design of potent dynorphin A-(1-9) analogues devoid of supraspinal motor effects in mice. Can. J. Physiol. Pharmacol. 75: 9-14, 1997.
17. 3H]desipramine binding associated with norepinephrine uptake sites in rat brain membranes. J. Neuroscience 10: 1515-1525, 1982.
18. LEMAIRE, S., LAFRANCE, L. AND DUMONT, M.: Synthesis and biological activity of dynorphin-A-(1-13) and the analogs substituted in the position 8 and 9. Int. J. Protein Peptide Res. 27: 300-305, 1986.
19. LITCHFIELD, J. T. AND WILCOXON, F.: A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96: 99, 1949.
20. LONG, J. B., KINNEY, R. C., MALCOLM, D. S., GRABBER, G. M. AND HOLADAY, J. W.: Intrathecal dynorphin A(1-13) and dynorphin A(3-13) reduce rat spinal cord blood flow by nonopioid mechanisms. Brain Res. 436: 374-379, 1987.
21. LONG, J. B., PETRAS, J. M., MOBLEY, W. C. AND HOLADAY, J. W.: Neurological dysfunction after intrathecal injection of dynorphin A-(1-13) in the rat. II. Non-opioid mechanisms mediate loss of motor, sensory and autonomic function. J. Pharmacol. Exp. Ther. 246: 1167-1174, 1988.
22. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-270, 1951.
23. MACDONALD, J. F. AND MOWAK, L. M.: Mechanism of blockade of excitatory amino acid ion channels. Trends Pharmacol. Sci. 11: 167-172, 1990.
24. MALENKA, R. C. AND NICOLL, R. A.: NMDA receptor-dependent synaptic plasticity: multiple forms and mechanisms. Trends Neurosci. 16: 521-526, 1993.
25. MASSARDIER, D. AND HUNT, P. F.: A direct non-opiate interaction of dynorphin-(1-13) with the N-methyl-d-aspartate (NMDA) receptor. Eur. J. Pharmacol. 170: 125-126, 1989.
26. MERRIFIELD, R. B.: Solid-phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85: 2149-2154, 1963.
27. NAKAZAWA, T., IKEDA, M., KANEKO, T., YAMATSU, K., KITAGAWA, K. AND KISO, Y.: Bestatin potentiates the antinociception but not the motor dysfunction induced by intracerebrally administered dynorphin-B in mice. Neuropeptides 13: 277-283, 1989.
28. NICHOLS, M. L., LOPEZ, Y., OSSIPOV, M. H., BIAN, D. AND PORRECA, F.: Enhancement of antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A-(1-13) or MK-801 in a nerve-ligation model of peripheral neuropathy. Pain 69: 317-322, 1997.
29. SMITH, A. P. AND LEE, N. M.: Pharmacology of dynorphin. Annu. Rev. Pharmacol. Toxicol. 28: 123-140, 1988.
30. SHUKLA, V. K., BANSINATH, M., DUMONT, M. AND LEMAIRE, S.: Selective involvement of kappa opioid and phencyclidine receptors in the analgesic and motor effects of dynorphin-A-(1-13)-Tyr-Leu-Phe-Asn-Gly-Pro. Brain Res. 591: 176-180, 1992.
31. SHUKLA, V. K. AND LEMAIRE, S.: Non-opioid effects of dynorphins: possible role of the NMDA receptors. Trends Pharmacol. Sci. 15: 420-424, 1994.
32. 3H]CGP 39653: a new N-methyl-d-aspartate antagonist radioligand with low nanomolar affinity in rat brain. Eur. J. Pharmacol. 192: 19-24, 1991.
33. SIRCAR, R., RAPPAPPORT, M., NICHTENBRAUER, R. AND ZUKIN, S. R.: The novel anticonvulsant MK-801: A potent and specific ligand of the brain phencyclidine/s receptor. Brain Res. 435: 235-240, 1987.
34. SKILLING, S. R., SUN, X., KURTZ, H. AND LARSON, A. A.: Selective potentiation of NMDA-induced activity and release of excitatory amino acids by dynorphin: possible roles in paralysis and neurotoxicity. Brain Res. 575: 272-278, 1992.
35. STEVENS, C. W. AND YAKSH, T. L.: Dynorphin A and related peptide administered intrathecally in the rat: A search for putative kappa opiate receptor activity. J. Pharmacol. Exp. Ther. 238: 833-838, 1986.
36. 1]dynorphin A peptide of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J. Pharmacol. Exp. Ther. 266: 121-124, 1993.
37. TALLARIDA, R. J. AND MURRAY, R. B.: Manual of Pharmacological Calculations with Computer Programs, 2nd ed., Springer, New York, 1987.
38. VANDERAH, T. W., LAUGHLIN, T., LASHBROOK, J. M., NICHOLS, M. L., WILCOX, G. L., OSSIPOV, M. H., MALAN, T. P. AND PORRECA, F.: Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rat: Blockade by MK-801 but not naloxone. Pain 68: 275-281, 1996.
39. WAGNER, J. J., TERMAN, G. W. AND CHAVKIN, C. Y.: Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus. Nature 363: 451-454, 1993.
40. WALKER, J. M., MOISES, H. C., COY, D. H., BALDRIGHI, G. AND AKIL, H.: Nonopiate effect of dynorphin and Des-Tyr-dynorphin. Science 218: 1136-1138, 1982.
41. WALKER, J. M., TUCKER, D. E., COY, D. H., WALKER, B. B. AND AKIL, H.: Desty-rosine dynorphin antagonizes morphine analgesia. Eur. J. Pharmacol. 185: 121-122, 1983.
42. WONG, E. H. AND KEMP, J. A.: Sites for antagonism on the N-methyl-d-aspartate receptor channel complex. Annu. Rev. Pharmacol. Toxicol. 31: 401-425, 1991.